Výsledky vyhledávání - "Vincristine/administration & dosage/adverse effects"

Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen

Autor: Monika Warmuth-Metz, Gerrit H. Gielen, André O. von Bueren, Marion Hoffmann, Brigitte Bison, Christof M. Kramm, Sabrina Bojko, Rolf D. Kortmann, Torsten Pietsch, Clemens Seidel

Publikováno v: Strahlentherapie und Onkologie, Vol. 194, No 3 (2018) pp. 215-224

As the efficacy of all pediatric high-grade glioma (HGG) treatments is similar and still disappointing, it is essential to also investigate the toxicity of available treatments. Prospectively recorded hematologic and nonhematologic toxicities of chil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9a2f3dff25077d9e8c76f0fb409e077
https://doi.org/10.1007/s00066-017-1218-6

Zobrazit plný text záznamu

Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Autor: Kathryn Pritchard-Jones, Anne-Sophie DEFACHELLES, Sucheta Vaidya, Gustaf Ljungman, Norbert Graf, Marc Ansari, Gordan Vujanic, Ricardo López Almaraz, Pedro Zubizarreta, Jan Godziński, Pamela Kearns, Anna Llort, Beatriz De Camargo, Leo Kager, Harm Van Tinteren, Ingrid Øra

Publikováno v: Pritchard-Jones, K, Bergeron, C, de Camargo, B, van den Heuvel-Eibrink, M M, Acha, T, Godzinski, J, Oldenburger, F, Boccon-Gibod, L, Leuschner, I, Vujanic, G, Sandstedt, B, de Kraker, J, van Tinteren, H, Graf, N & SIOP Renal Tumours Study Group 2015, ' Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001) : an open-label, non-inferiority, randomised controlled trial ', Lancet, vol. 386, no. 9999, pp. 1156-1164 . https://doi.org/10.1016/S0140-6736(14)62395-3
Lancet, 386(9999), 1156-1164. Elsevier Limited
The Lancet, Vol. 386, No 9999 (2015) pp. 1156-64

BACKGROUND: Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is importa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05386b33380bcd2146bacb31bab8c77a
https://doi.org/10.1016/s0140-6736(14)62395-3

Zobrazit plný text záznamu

DV-ICE, intensive induction and early transplantation for adult patients with acute lymphoblastic leukemia: a phase II study

Autor: Alois Gratwohl, Jakob Passweg, M. Wernli, André Tichelli, Mario Bargetzi, Christine Dudler

Publikováno v: European Journal of Haematology, Vol. 83, No 6 (2009) pp. 512-518

OBJECTIVES: Eighty percent of adult patients with acute lymphoblastic leukemia (ALL) achieve a complete remission (CR) but only 30-40% are long term survivors. Best treatment strategies remain to be defined. The role of induction intensity, first rem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2a535815c45f632c7eb0d8505f974cf
https://archive-ouverte.unige.ch/unige:19783

Zobrazit plný text záznamu

Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone

Autor: Christou, L., Hatzimichael, E., Chaidos, A., Tsiara, S., Bourantas, K. L.

Primary plasma cell (PCL) leukemia is a rare lymphoproliferative disorder characterized by a malignant proliferation of plasma cells in the bone marrow and peripheral blood. Survival with standard therapy using melphalan is very poor. Doxorubicin enc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::4a976e6295e8ce34b40a500536eaa612
http://olympias.lib.uoi.gr/jspui/handle/123456789/20210

Zobrazit plný text záznamu

A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

Autor: Groves, M. D., Maor, M. H., Meyers, C., Kyritsis, A. P., Jaeckle, K. A., Yung, W. K., Sawaya, R. E., Hess, K., Bruner, J. M., Peterson, P., Levin, V. A.

PURPOSE: To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::4123ce5b23a9bce83bdbbb6935ab6966
http://olympias.lib.uoi.gr/jspui/handle/123456789/24282

Zobrazit plný text záznamu

Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases?

Autor: Pavlidis, Nicholas, Nikolaou, N., Ch, F. Tolis, Orfanos, S., Tolis, G.

Publikováno v: Medical and pediatric oncology

A patient with hypogonadotropic hypogonadism owing to endogenous gonadotropin releasing hormone deficiency, who developed Hodgkin's disease is described. Chemotherapy administration caused prolonged and life‐threatening myelosuppression; androgen s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5467e439147cb2fe119ecf21ef03a05
https://pubmed.ncbi.nlm.nih.gov/2664441

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání